COMPANY PRESENTATION
Evolution from branded generics to innovations
COMPANY PRESENTATION
Company highlights
Founded in
Unique hybrid model combining positive cash flows and integrated pharma business experience with a diversified pipeline of highly innovative programs Disciplined new program selection, focusing on un-met medical needs.
Driven by the best people
+
employees Highly experienced management team Founder-led teams with scientific backgrounds:
+
scientists.
Broad pipeline of
clinical stage assets and multiple identified leads targeting large market opportunities in neuropsychiatry, oncology, metabolism & inflammation Potential blockbusters with wholly owned IP Advanced early-stage pipeline:
innovative programs in pre-clinical.
Footprint in
>
countries Diversified enabling internal resources portfolio leading to the improved probability of success Collaborating at center of the biotech ecosystem.
COMPANY PRESENTATION
Led by a seasoned management team
Maciej Wieczorek, PhD
CEO, President of the Management BoardFounder and President of the Management Board of Celon Pharma PhD in Medical Biology at the Medical University of Lodz (PL) Scholarship of New University of Lisbon in Portugal, while also completed MBA at the Warsaw School of Economics and the University of Minnesota Inventor or co-inventor of several patent applications for classic chemical and biotechnological drugs, as well as the driving force for the launch of several of the best-selling drugs in Poland
Dorota Zwolińska
CFOManager with 15 years of experience in broadly understood financial analysis and controlling. She gained her experience at EY (formerly Ernst & Young), where in 2006-2013 she participated in numerous financial due diligence processes for the needs of mergers and acquisitions. In the years 2013-2016 as the Deputy Director at PKP CARGO S.A. she was responsible for building the operational and financial controlling functions. She was a member of the Supervisory Board of PKP Cargotabor sp.z o.o. in the years 2014-2016. In the years 2016-2021 she was employed at RADPOL SA, as the Financial Director.
COMPANY PRESENTATION
Segment dynamics - FY 2021/2022
Well balanced business model.
BRANDED
GENERICS
BRANDED GENERICS
Key strategic competences
Various pharmaceutical forms development
Intellectual property
management
GMP Manufacturing - dry forms and dry powder inhalers
Global regulatory
& supply chain
Full size commercial infrastructure in Poland and global network of partnerships outside Poland
Various pharmaceutical forms development
Intellectual property management
GMP Manufacturing - dry forms and dry powder inhalers
Global regulatory & supply chain
Full size commercial infrastructure in Poland and global network of partnerships outside Poland
BRANDED GENERICS
sales 2022
BRANDED GENERICS
Improved sales dynamics in Poland in 2022
Sell-out data are sourced from the pharmacy market and include margins of the distributors. Sell-out data do not constitute a basis for recognition of the Company's revenues and should not be considered as statutory accounting data reported by the Company.
BRANDED GENERICS
incubation of technologies and capabilities and strong and growing source of cash flows
2020
. mln USD
2021
. mln USD*
*without profit sharing
2022
. mln USD
INNOVATIVE
BUSINESS
INNOVATIVE BUSINESS
Therapeutic areas
INNOVATIVE BUSINESS
New R&D centre: total capacity increased by ~3x
200+
scientists
More than
46.000 m²
NEW
• Recombinant biotech: mammalian & microbiomes Modern analytics
• Modern analytics
• mRNA platform: core competencies in mRNA technology in one place
INNOVATIVE BUSINESS
Diversified platforms drives strong pipeline
INNOVATIVE BUSINESS
News flow & key milestones 2023/2024
INNOVATIVE BUSINESS
Partnering strategy 2023/2024
INNOVATIVE BUSINESS
Strategic focus
During the last 5 years, Celon has delivered 6 successful data readouts, initiated 11 clinical trials, and raised capital through EU-found financings and public offerings.
Celon is led by a strong management team that brings to the organization a combined track record of managing national and global companies.
We aim to be resource- and capital-efficient in the development of our therapeutic candidates by selectively accessing complementary expertise and infrastructure through strategic partnerships.
We are building a leading innovative R&D and Clinical Development team that we believe has a unique perspective about how to identify high-potential product candidates and unlock their full value.
We are actively seeking opportunities to partner in terms of our clinical and preclinical programs by acquisition, in-licensing, or co-development.
During the last 5 years, Celon has delivered 6 successful data readouts, initiated 11 clinical trials, and raised capital through EU-found financings and public offerings.
Celon is led by a strong management team that brings to the organization a combined track record of managing national and global companies.
We aim to be resource- and capital-efficient in the development of our therapeutic candidates by selectively accessing complementary expertise and infrastructure through strategic partnerships.
We are building a leading innovative R&D and Clinical Development team that we believe has a unique perspective about how to identify high-potential product candidates and unlock their full value.
We are actively seeking opportunities to partner in terms of our clinical and preclinical programs by acquisition, in-licensing, or co-development.
Contact
Contact Us
Celon Pharma S.A
Ogrodowa 2A,
05-092 Łomianki / Kiełpin
Email:
Call:
+48 22 751 59 33